Page last updated: 2024-09-02

ci 988 and Drug Withdrawal Symptoms

ci 988 has been researched along with Drug Withdrawal Symptoms in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blommaert, AG; Ducos, B; Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O	1
Abelson, JL; Bammert-Adams, J; Curtis, GC; Fantone, R; Nesse, R; Pyke, RE	1
Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Ruiz, F	1
Roques, BP; Valverde, O	1
Little, HJ; Wilson, J	1
Little, HJ; Watson, WP; Wilson, J	1
Field, MJ; Hughes, J; Singh, L; Vass, CA; Woodruff, GN	1
Hökfelt, T; Horwell, DC; Hughes, J; Wiesenfeld-Hallin, Z; Xu, XJ	1
Costall, B; Domeney, AM; Hughes, J; Kelly, ME; Naylor, RJ; Woodruff, GN	1

Trials

1 trial(s) available for ci 988 and Drug Withdrawal Symptoms

Article	Year
The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam. Biological psychiatry, 1995, Jan-01, Volume: 37, Issue:1 Topics: Adult; Alprazolam; Cross-Over Studies; Double-Blind Method; Humans; Hypothalamo-Hypophyseal System; Indoles; Meglumine; Middle Aged; Pituitary-Adrenal System; Receptors, Cholecystokinin; Substance Withdrawal Syndrome	1995

Article

Year

The effects of central cholecystokinin receptor blockade on hypothalamic-pituitary-adrenal and symptomatic responses to overnight withdrawal from alprazolam.

Biological psychiatry, 1995, Jan-01, Volume: 37, Issue:1

Topics: Adult; Alprazolam; Cross-Over Studies; Double-Blind Method; Humans; Hypothalamo-Hypophyseal System; Indoles; Meglumine; Middle Aged; Pituitary-Adrenal System; Receptors, Cholecystokinin; Substance Withdrawal Syndrome

1995

Other Studies

8 other study(ies) available for ci 988 and Drug Withdrawal Symptoms

Article	Year
Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308. British journal of pharmacology, 1995, Volume: 114, Issue:5 Topics: Analgesics; Animals; Behavior, Animal; Binding, Competitive; Body Temperature; Diprenorphine; Disulfides; Drug Combinations; Drug Synergism; Enkephalins; Indoles; Male; Meglumine; Mice; Morphine; Motor Activity; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome; Weight Loss	1995
Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism. British journal of pharmacology, 1996, Volume: 119, Issue:1 Topics: Analgesics; Animals; Disulfides; Drug Combinations; Enkephalins; Indoles; Male; Meglumine; Methadone; Morphine; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome	1996
Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Neuroscience letters, 1998, Mar-06, Volume: 244, Issue:1 Topics: Animals; Anti-Anxiety Agents; Avoidance Learning; Benzodiazepinones; Cholecystokinin; Conditioning, Classical; Devazepide; Indoles; Male; Meglumine; Morphine Dependence; Peptide Fragments; Phenylurea Compounds; Rats; Rats, Wistar; Substance Withdrawal Syndrome	1998
CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome. Pharmacology, biochemistry, and behavior, 1998, Volume: 59, Issue:4 Topics: Acoustic Stimulation; Alcoholism; Animals; Anti-Anxiety Agents; Behavior, Animal; Central Nervous System Depressants; Dipeptides; Ethanol; Excitatory Amino Acid Agonists; Handling, Psychological; Indoles; Male; Meglumine; Mice; Mice, Inbred Strains; N-Methylaspartate; Receptors, Cholecystokinin; Seizures; Substance Withdrawal Syndrome	1998
CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze. Psychopharmacology, 1998, Volume: 137, Issue:2 Topics: Animals; Anxiety; Dipeptides; Ethanol; Indoles; Male; Maze Learning; Meglumine; Mice; Motor Activity; Rats; Rats, Wistar; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Receptors, Serotonin; Substance Withdrawal Syndrome	1998
The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. British journal of pharmacology, 1992, Volume: 105, Issue:1 Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Diazepam; Drug Administration Schedule; Indoles; Light; Male; Meglumine; Mice; Mice, Inbred Strains; Receptors, Cholecystokinin; Substance Withdrawal Syndrome	1992
CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat. British journal of pharmacology, 1992, Volume: 105, Issue:3 Topics: Animals; Behavior, Animal; Drug Tolerance; Indoles; Injections, Intraperitoneal; Male; Meglumine; Morphine; Morphine Dependence; Naloxone; Pain Measurement; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Substance Withdrawal Syndrome	1992
Anxiolytic effects of CCK-B antagonists. Neuropeptides, 1991, Volume: 19 Suppl Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Callitrichinae; Diazepam; Indoles; Meglumine; Mice; Rats; Receptors, Cholecystokinin; Substance Withdrawal Syndrome	1991